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INTRODUCTION 
Among the considerations governing the therapy of 
staphylococcal endocarditis, several parameters are of 
importance as they determine: the kind of antibiotic to 
be used, the use of a single agent or antibiotic combin- 
ation, the duration of the required therapy period, the 
indications for surgery, and milestones during the 
general management of the patient. 
Factors determining therapy can be divided into 
those depending on the host and those depending on 
the pathogen. 
Host factors which are of importance are: 
the site of the infection in the heart; 
the age of the patient; 
the presence of septic emboli in various organs; 
the presence of a previous episode@) of endo- 
the use of intravenous illicit drugs; 
the nature of the valve lesion; 
the functional class of the patient; 
the presence of a foreign implant in the heart or 
vascular system (valve, pacemaker, patch, Dacron, 
etc). 
carditis; 
Among bacterial factors, the most important are: 
the presence of Staphylococcus aureus that is 
methicillin sensitive (MSSA); 
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the presence of S. uureus that is methicillin 
resistant (MRSA); 
the presence of coagulase-negative Staphylococcus 
that is methicillin susceptible (MSSE); 
the presence of coagulase-negative Staphylococcus 
that is methicillin resistant (MRSE); 
the presence of p-lactam-tolerant staphylococci 
-the determination of tolerance is not standard- 
ized at the present time and may be dependent 
on the method of determination used; 
the presence of methicillin-susceptible S. auieus 
that acquires methicillin resistance by stepwise 
selection due to multiple mutations on the 
chromosome (MODSA). 
EPIDEMIOLOGY OF S, AUREUS ENDOCARDITIS 
The mortality of the disease is still approximately 40% 
[l-81; however, improved survival has been noted (19% 
mortality) in recent series [4]. In the review published 
by Sandre and Shafran [5], S. aureus represented 30% 
of the cases of native valve endocarditis: 40% of them 
developed in intravenous drug abusers and 18% were 
late prosthetic valve endocarditis (PVE) cases. The overall 
mortality was 28%. Risk groups for high mortality 
include [4-81: 
age >50 years; 
male gender; 
left-sided endocarditis; 
involvement of the central nervous system. 
*The group of experts comprised: C. Carbon, D.T. Durack, 
P. Francioli, E. Gutschik, C. Leport, !? Moreillon, 
K. Ngu-Blackett, E. Rubinstein, D. Stamboulian, J. Thompson, 
J.T.M. Van der Meer and W. R. Wilson. 
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EPIDEMIOLOGY OF COAGULASE-NEGATIVE 
STAPHYLOCOCCAL ENDOCARDITIS (ON A NATIVE 
VALVE) 19-1 21 
Pre-existing valve abnormality is present in three- 
Acute onset occurs in a quarter of the cases, 
Neurologic disturbances are detected in a quarter 
Mortality due to infection occurs in a third of the 
cases. 
Previously, the majority of coagulase-negative 
staphylococci (CNS) were methicillin suscept- 
ible; presently, the majority are methicillin 
resistant. 
quarters of the cases. 
of the cases. 
EPIDEMIOLOGY OF PVE [13-201 
In patients with a prosthetic valve and bacteremia, 25% 
of blood isolates are CNS; of patients with a prosthetic 
valve and with bacteremia due to this microorganism, 
25-33'% will develop endocarditis with this pathogen. 
A lower rate, roughly 1196, of patients with a prosthetic 
valve will have S. aureus isolated from their blood 
cultures; of those, roughly 20% will develop endo- 
carditis on their prosthetic valve. 
Ofpatients with PVE, some 30% will develop their 
disease within 60 days of valve insertion and will 
therefore be classified as early PVE, while about 70% 
will develop their infection >60 days after surgery 
and will be classified as late PVE. For coagulase- 
negative staphylococcal PVE, the early onset of 
infection associated with the operation may occur later 
than 60 days and be extended to 6 or even 12 months. 
Microorganisms isolated from cases of PVE (about 
500 patients from various series) demonstrate that CNS 
are isolated from 25-60% of cases; the majority of the 
organisms (>85%) will be MKSE. 
S. rpidermidis was exclusively observed on pros- 
thetic valves in the review published by Sandre and 
Shafran (5): 43% of the early infections, and 15% of the 
late ones. 
S. aureus is isolated from about 20% of cases. Of  
those, 1.4-3.0% will have acquired their infection 
nosocomially. 
EPIDEMIOLOGY OF ENDOCARDITIS IN 
INTRAVENOUS DRUG ADDICTS [21-261 
Among IVlIA patients with endocarditis, most infec- 
tions occur in the right heart, with the tricuspid valve 
being involved in the majority of cases. Eighty per cent 
of the vegetations will have a diameter of < I  cni on 
echocardiographic examination. MSSA is expected to 
be isolated from about 80% of the cases, and MRSA 
from about 14% A combination of S. auieus with 
another pathogen (polymicrobial endocarditis) will 
occur in about 5% of cases. 
The mortality of IVDA with right-sided endo- 
carditis patients is around 8% and is not higher in 
patients with MRSA than in patients with MSSA. 
THERAPEUTIC CONSIDERATIONS 
The pattern of antibiotic penetration into vegetations 
is variable and the distribution of an antibiotic 
throughout the vegetation may be heterogeneous [27]. 
Altered conditions of the bacteria within the 
vegetation produce bacteria with variant morphology, 
altered metabolism and formation of a glycocalyx; all 
these factors may change the antibiotic susceptibility of 
the intravegetational bacteria. 
In order to be effective in the treatment of 
endocarditis, an antibiotic must be active in vitro, reach 
suficiently high intravegetative concentrations and 
have sufficiently long contact with the bacteria. 
Furthermore, the antibiotic should not be adversely 
influenced by bacterial enzymes and local intra- 
vegetational conditions. Therapy must be of long 
enough duration to prevent recurrences and ensure 
bacterial eradication. Therapy must be bactericidal in 
order to reduce the risk of relapse and avoid clinical 
complications. Effective therapy will allow the shorten- 
ing of the duration of therapy. Therapy should also be 
aimed at reducing the possibility of the emergence of 
bacterial resistance [28]. 
In patients with community-acquired left-sided 
S. aureus endocarditis, transthoracic or transesophageal 
echocardiography is indicated. A computerized scan of 
the body and brain, with particular reference to the 
spleen, is recommended in patients with staphylococcal 
endocarditis acquired in the community, in view of the 
high rate of metastatic foci, abscesses and hemorrhages 
due to the long duration of sustained bacteremia in 
such patients. Findings of CT and other techniques 
may have therapeutic implications, as they may indicate 
prolonged therapeutic periods after heart surgery or 
drainage of quiescent abscesses. 
Kegarding in vitro studies, the main findings for 
MSSA indicate that the rate at which the combination 
of semisynthetic penicillin and an aminoglycoside kills 
MSSA incorporated in fibrin clots is three-fold greater 
than that of semisynthetic penicillins alone. In animal 
studies, the combination of a p-lactam and an amino- 
glycoside sterilized the vegetations more rapidly than 
p-lactam alone (3-4 days versus 7-10 days). Also, in 
patients with right-sided endocarditis the duration of 
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bacteremia was reduced in patients who were treated 
with the combination of nafcillin and gentamicin 
compared to those treated with nafcillin alone. In the 
in vitro fibrin clot model, nafcillin was more rapidly 
bactericidal than vancomycin, and vancomycin and 
teicoplanin had low activity at a low concentration 
(3 mg/kg) and equal activity at high concentrations 
(1 5 mg/g) when co-administered with gentamicin (6 
log kill over 72 h) [28,29]. In animal experiments as 
well, the combinations of vancomycin and gentamicin 
and vancomycin and rifampin were more effective 
than vancomycin alone. Furthermore, development of 
resistant mutants was observed in MSSA from vegeta- 
tions of animals treated with low doses of teicoplanin 
but not with vancomycin. 
CLINICAL STUDIES 
Vancomycin versus p-lactam [21-24,30-321 
Therapy with semisynthetic penicillin also produces 
superior clinical results to therapy with vancomycin in 
patients infected with staphylococci that are methicillin 
susceptible. 
Some authorities recommend the use of vanco- 
mycin in constant infusion over 24 h, allowing a 
possible reduction of the daily dose. 
Vancomycin combined with an aminoglycoside 
was associated with a far greater failure rate (about 
50%) than that observed in patients who received the 
combination of semisynthetic penicillin and an 
aminoglycoside (6%). In patients infected with MRSA 
the failure rate of the combination of vancomycin and 
rifampin varied between 10% and 66% but averaged 
11.1%. The failure rate of vancomycin alone was 
double that of the combinations of vancomycin and 
rifampin or vancomycin and gentamicin (30% versus 
15%). These data, albeit not always controlled, suggest 
that for staphylococci resistant to methicillin the 
combination of vancomycin and gentamicin or 
rifampin is expected to produce better therapeutic 
results than therapy with vancomycin alone. Ifthe strain 
is susceptible to methicillin, the combination of a 
semisynthetic penicillin with an aminoglycoside, e.g. 
gentamicin 3-4 mg/kg per day in divided dosages, is 
superior to vancomycin alone or vancomycin in 
Combination with an aminoglycoside or rifampin. 
When vancomycin is administered, blood trough 
levels should be determined serially to check that 
adequate therapy is being given. 
When rifampin is introduced into therapy, it 
should be added to the combination of a p-lactam or 
vancomycin with an aminoglycoside to reduce the 
development of rifampin resistance in the presence of 
foreign bodies (prosthetic valve). 
Teicoplanin 
The data on teicoplanin therapy of MRSA are limited. 
Failures of MRSA endocarditis during or following 
therapy with teicoplanin have been reported [33,34] 
and may be of particular importance for nosocomially 
acquired MRSA cases [35]. 
The need to determine blood levels and to mo&G 
the dose accordingly may also be of importance, partic- 
ularly in IVDA patients. 
Therefore, teicoplanin should be used when 
vancomycin cannot be administered. 
THERAPY OF MSSA ENDOCARDITIS (Table 1 )  
As first line therapy 
A p-lactamase-resistant penicillin (flucloxacillin, 
methicillin or oxacdin) for 4-6 weeks with or with- 
out gentamicin for 5-7 days is recommended. The 
recommended daily dose of gentamicin is 3-4 mg/kg 
per day in patients with normal renal function, in 1-3 
daily doses. Some authorities administer gentamicin in 
a single daily dose; however, no consistent data exist for 
this mode of administration in staphylococcal endo- 
carditis. 
In patients with an uncomplicated presentation and 
good initial response, many authorities use a 4-week 
course of semisynthetic penicillin plus gentamicin for a 
short period (3-5 days). 
Some authorities prolong the duration of genta- 
micin co-therapy to 2 weeks, both in the patients with 
uncomplicated presentation and a good clinical re- 
sponse, and in patients with a delayed clinical response 
and a complicated course. 
Table 1 MSSA endocarditis: recommendations 
First line 
p-lactamase-resistant penicillin for 4-6 weeks * gentanucin 
5-7a daysb 
In cases of central nervous 
Persistent bacteremia 
Metastatic foci 
penicillin (6 weeks) 
+ gentamicin (5-7 days') 
? rifampicin 
system involvement 
01 
vancomycin 4 4  weeks 
+ gentamicin 5-7 days' 
Second line 
First-generation cephalosporin for 4 4  weeks + gentamicin 5-7 
days" 
a In cases of uncomplicated presentation and good initial response, 
4 weeks + gentamlcin. 
'Some authorities administer gentamicin for 2 weeks. 
3S30 C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  4 S u p p l e m e n t  3 
Gentamicin serum levels should be monitored in 
all patients twice weekly, and more frequently in 
patients with renal insufficiency, in the aged, and in 
patients receiving concomitant nephrotoxic agents. 
Trough levels should be around 1 mg/L and the desired 
peak level over 3 mg/L. 
Some authorities add 300-600 mg rifanipin to 
such complicated patients, while others refrain from 
adding this antibiotic to the j3-lactam-aminoglycoside 
combination, as p-lactam and rifampin may be 
antagonistic in non-foreign body MSSA. 
In j3-lactam-allergic patients, or as an option in 
patients who cannot tolerate p-lactam therapy, vanco- 
niycin for 4-6 weeks and an aminoglycoside for 5-7 
days are recommended. Here too, in patients with 
uncomplicated presentation and a good initial response, 
4 weeks of therapy with vancomycin (plus a short 
course of gentamicin) may be sufficient. 
In patients with central nervous system involve- 
ment, persistent bacteremia and metastatic foci, a 
6-week course of semisynthetic penicillin is recom- 
mended along with a short (5-7 days) or prolonged (14 
days) course of aminoglycoside therapy. 
Second-line therapy 
Certain cephalosporins, e.g cefamandole or cefuroxinie 
for 4-6 weeks co-administered with gentamicin for 5-7 
days, are recommended (in uncomplicated cases with a 
satisfactory initial response, a 4-week course of therapy 
may be adequate). Third-generation cephalosporins, 
such as cefotaxinie and ceftriaxone, have also been 
successfully used in individual cases; however, no series 
large enough to demonstrate their efficacy have been 
published. 
THERAPY OF MRSA ENDOCARDITIS (Table 2) 
First-line therapy 
Vanconiycin for 4-6 weeks with gentamicin for 5-7 
days is recommended, The evidence in support of a 
prolonged course of gentaniicin administration is not 
adequately documented or well established, and a long 
course is associated with a higher rate of adverse events 
than is a shorter course. Nevertheless, some authorities 
use gentaniicin for 2 weeks, while others do not add 
gentaniicin at all to vancomycin therapy. 
I n  non-responders, vancomycin plus rifampicin 
plus gentamicin for 4-6 weeks is recommended. 
Second-line therapy 
Vancomycin combined with trimethoprin- 
sulfamethoxazole for 4-6 weeks is sonietimes used. For 
non-rmponders, vancomycin plus rifanipin plus a 
fluoroquinolone (preferably ofloxacin or ciprofloxacin), 
Table 2 MRSA endocarditis: recommendatlons 
First line 
Vancomycin 4-6 weeks + gentamicin 5-7 
For non-responders: vancomycin + rifampicin + gentamicin 4-6 
wee ky . 
Second line 
Vancomycin + trinirthoprim-sulfamethoxazole for 4-6 weeks 
For non-responders: vanconivcin + rifampicin + ciprofloxacin 
(FQ) 
or 
rifampicin + F Q  
The evidence in support of prolongrd gentamicin administration 
Some authorities treat with vaiicoinycin alone, \ \Me others use 
IS not well documented or established. 
gentamkin for 2 weeks. 
or rifampin plus a fluoroquinolone for 6 weeks, have 
been successfully used. 
THERAPY OF RIGHT-SIDED ENDOCARDITIS CAUSED 
BY MSSA IN IVDAs (Table 3) 
Included in this category are patients with pulmonary 
emboli presumed to be septic and patients whose 
isolates are gentarnicin susceptible. Excluded are 
patients with hemodynamic instability. with systemic 
emboli, with metastatic foci, and with vegetations 
on echocardiography measuring >2  cm, and patients 
whose isolates are gentamicin resistant. 
THERAPY OF RIGHT-SIDED ENDOCARDITIS CAUSED 
BY MSSA IN NON-IVDAS 
In the absence ofan underlying cardiac lesion and with 
no extracardiac foci, as is the usual case in patients with 
indwelling central venous catheters used for 
hyperalimentation or chemotherapy administration, a 
2-week course of therapy is recommended as long as a 
good clinical response is observed within 96 h of 
therapy, without any coiiiplications (no hemodynamic 
disturbance, no emboli, no septic metastases) and in the 
absence of large vegetations [22]. 
First-line therapy 
A 2-week course of a semisynthetic penicillin plus low- 
dose gentamicin is recommended. Gentamicin should 
be administered in two daily administrations, but one 
dose a day may be sufficient. Gentamicin blood levels 
should be measured twice weekly. 
Another option is a 4-week course of nafcillin 
without the addition of gentamicin. A report from 
Spain suggests that a semisynthetic penicillin alone for 
R u b i n s t e i n  e t  a t :  S t a p h y l o c o c c a l  e n d o c a r d i t i s - r e c o m m e n d a t i o n s  f o r  t h e r a p y  3S31 
Table 3 Right-sided endocarditis caused by MSSA in IVDAs 
Included: gentamicin-susceptible isolates 
Pulmonary emboli 
Excluded gentamicin-resistant isolates 
Hemodynamic instability 
Systemic emboli 
Metastatic foci 
Vegetation on echo >2 cm3 
Preferred therapy 
Two weeks with p-lactamase-resistant penicillin + gentamicin. In two daily administrations one dose a day may 
Nafcillin for 4 weeks without gentamicin 
Prognosis: 92% cure; 3% fadure 
be sufficient) (measure gentamicin blood levels for 5-7 days) 
Optional therapy 
Two weeks with vancomycin + gentamicin for 5-7 days 
Two weeks of p-lactam therapy alone 
Second choice 
Four weeks of ciprofloxacin 750 mg. b.i.d. + rifampin 300 mg. b i d .  [28] 
a Some authorities use aminoglycosides for 2 weeks 
2 weeks may be sufficient in patients with an un- 
complicated course [36]. With any of these regimens, 
the prognosis should be a 92% cure rate and a 3% failure 
rate. 
An optional therapy is a 2-week course of 
vancomycin with gentamicin for 5-7 days. 
Second-line therapy 
A 4-week course of oral ciprofloxacin 750 mg twice 
daily and rifampin 300 mg twice daily has also been 
reported to be successful [28]. 
A prospective, randomized non-blinded trial has 
confirmed the potential of an oral regimen combining 
ciprofloxacin and rifampin, with less toxicity than the 
intravenous therapy [37]. 
THERAPY OF PVE CAUSED BY S. AUREUS 
(Table 4) 
MSSA 
first-line therapy 
A semisynthetic penicillin and an aminoglycoside (for 
a 3-7-day period) and early surgery and possibly the 
addition of rifampin to the combination are recom- 
mended. If the surgical specimens are culture-negative, 
the entire duration of the therapy course should be 4-6 
weeks. 
In the presence of myocardial abscesses, necrotic 
tissue, evidence of inflammation, involvement of the 
annulus, pseudoaneurysm, other surgical pathologic 
findings or positive surgical cultures; 4-6 weeks of 
therapy following surgery regardless of the presurgery 
therapy period is recommended, with a semisynthetic 
penicillin plus aminoglycoside for a 5-7-day period. 
Table 4 Prosthetic valve endocarditis-S. aureus 
MSSA 
P-Lactamase-resistant penicillin- + gentamicin for 5-7 daysa 
+ early surgery (krifampicin)', if surgical specimens are 
culture-negative, entire duration of therapy 4-6 weeks 
In the presence of myocardial abscess or involvement of the 
annulus or pseudoaneurysm or positive cultures, 4 4  weeks 
of therapy following surgery 
MRSA 
Immediate operation' followed by vancomycin for 4-6 weeks 
+ gentamicin for 5-7 daysa (2rifampicin k FQ) 
a Some authorines extend ammoglycoside therapy for 2 weeks. 
higher than with homograft and therefore the presence of 
prosthetic material requires a prolonged therapy course. 
The risk of re-infection with prosthetic material is believed to be 
MRSA 
first-line therapy 
Immediate surgery followed by therapy with vanco- 
mycin for 4-6 weeks and aminoglycoside for 5-7 days 
is recommended. Some authorities extend the course 
of gentamicin to 2 weeks, while others add rifampin 
alone or rifampin and a fluoroquinolone [17,18]. 
THERAPY OF COAGULASE-NEGATIVE STAPHYLO- 
COCCAL ENDOCARDITIS ON A NATIVE VALVE [ l l ]  
It is recommended to start with vancomycin therapy 
alone or in combination with gentamicin. A switch to 
a semisynthetic penicillin should be undertaken if the 
methicillin MIC of the organism is <0.5 mg/L. 
First-generation cephalosporins are not recom- 
mended. 
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For MSSE, a semisynthetic penicdlin for 4-6 weeks 
and aminoglycoside for 2 weeks are recommended. 
Some authorities use a shorter course of gentamicin 
therapy. The combination seems to offer a better 
therapy outcome than that achieved with the semi- 
synthetic penicillin alone (%!‘%I versus 72%). If the 
isolate I S  gentamicin resistant, some authorities add 
fluoroquinolone with or without rifampin for the 
entire therapy course [ 1 I ,  121. 
For MRSE, vancomycin for 4-6 weeks along with 
gentamicin for courses as previously discussed is 
recommended. 
THERAPY OF PVE CAUSED BY CNS [l I ]  
I n  this category, individual antibacterial sensitivities of 
the particular infective strain require individual tailor- 
ing of therapy. 
Many CNS are rifampin resixant and many x-e 
gentamicin resistant. If the isolated strain is, however, 
rifampin and gentamicin wsceptible, the recom- 
mended therapy is vancomycin combined with 
rifampin for 6 weeks combined with gentamicin for the 
first 2 weeks of therapy. 
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